National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
NCI Drug Dictionary
Page Options
Print This Page  Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

NCI Responds to Hurricanes

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

anti-B4 blocked ricin immunotoxin
An immunotoxin comprised of an anti-B4 (anti-CD19) murine monoclonal antibody linked to the modified plant-derived toxin blocked ricin. The antibody moiety of anti-B4 blocked ricin immunotoxin binds to B lymphocytes that express B4; after internalization of the immunotoxin by the B4-expressing B cell, the ricin moiety cleaves the N-glycosidic bond between the ribose and adenine base at position 4324 in the B lymphocyte 28S ribosomal RNA, resulting in ribosome inactivation, inhibition of protein synthesis, and cell death. "Blocked" ricin is ricin which has been chemically modified such that the lectin binding sites of the B chain (galactose-binding sites) have been blocked by covalent attachment of affinity ligands, leaving the ribosome-inactivating activity of the ricin A chain intact. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonyms:anti-B4 blocked ricin
monoclonal antibody anti-B4 blocked ricin
Abbreviations:anti-B4-BR
MOAB anti-B4-bR



Previous:aniline mustard, annamycin liposomal, Ansaid, Antabuse, anti-1-amino-3-[18F ]fluorocyclobutane-1-carboxylic acid
Next:anti-CCL-2 human monoclonal antibody CNTO 888, anti-CD137 monoclonal antibody, anti-CD19 fully human monoclonal antibody MDX-1342, anti-CD19-DM4 immunoconjugate SAR3419, anti-CD19/anti-CD3 recombinant bispecific monoclonal antibody MT103

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov